The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1057
July 16, 1999
View Complete Issue         Table of Contents 2019 
Amprenavir: A New HIV Protease Inhibitor
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Amprenavir: A New HIV Protease Inhibitor
July 16, 1999 (Issue: 1057)
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Amprenavir: A New HIV Protease Inhibitor
Article code: 1057b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.